IL133277A0 - Ligands, including antibodies, showing reactivity against endocrine cells - Google Patents

Ligands, including antibodies, showing reactivity against endocrine cells

Info

Publication number
IL133277A0
IL133277A0 IL13327798A IL13327798A IL133277A0 IL 133277 A0 IL133277 A0 IL 133277A0 IL 13327798 A IL13327798 A IL 13327798A IL 13327798 A IL13327798 A IL 13327798A IL 133277 A0 IL133277 A0 IL 133277A0
Authority
IL
Israel
Prior art keywords
antibodies
ligands
endocrine cells
including antibodies
reactivity against
Prior art date
Application number
IL13327798A
Other languages
English (en)
Original Assignee
Rogers Arpi Matossian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9715281A external-priority patent/GB2327423B/en
Priority claimed from GBGB9810676.8A external-priority patent/GB9810676D0/en
Application filed by Rogers Arpi Matossian filed Critical Rogers Arpi Matossian
Publication of IL133277A0 publication Critical patent/IL133277A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
IL13327798A 1997-07-21 1998-07-20 Ligands, including antibodies, showing reactivity against endocrine cells IL133277A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9715281A GB2327423B (en) 1997-07-21 1997-07-21 Ligands, including antibodies, showing reactivity against endocrine cells for use in therapy and diagnosis
GBGB9810676.8A GB9810676D0 (en) 1998-05-18 1998-05-18 Ligands including antibodies showing reactivity against endocrine cells for use in therapy and diagnosis
PCT/GB1998/002151 WO1999005175A2 (en) 1997-07-21 1998-07-20 Diagnosis and treatment of diseases using anti-anti-t-cell receptor vbeta anti-bodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein i (esrp1)

Publications (1)

Publication Number Publication Date
IL133277A0 true IL133277A0 (en) 2001-04-30

Family

ID=26311906

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13327798A IL133277A0 (en) 1997-07-21 1998-07-20 Ligands, including antibodies, showing reactivity against endocrine cells
IL133277A IL133277A (en) 1997-07-21 1999-12-02 Ligands, including antibodies, show a response against endocrine cells
IL176076A IL176076A (en) 1997-07-21 2006-05-31 Polypeptides and their segments bound by an antibody or segment of an antibody that responds to an anti-TCR V beta antibody and their uses

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL133277A IL133277A (en) 1997-07-21 1999-12-02 Ligands, including antibodies, show a response against endocrine cells
IL176076A IL176076A (en) 1997-07-21 2006-05-31 Polypeptides and their segments bound by an antibody or segment of an antibody that responds to an anti-TCR V beta antibody and their uses

Country Status (21)

Country Link
US (2) US6689359B1 (de)
EP (2) EP1595951A1 (de)
JP (1) JP2002511765A (de)
KR (2) KR100670070B1 (de)
CN (1) CN1330754C (de)
AT (1) ATE297983T1 (de)
AU (1) AU758455B2 (de)
BR (1) BR9810118A (de)
CA (1) CA2296842C (de)
CU (1) CU23412A3 (de)
DE (1) DE69830588T2 (de)
DK (1) DK0998556T3 (de)
EA (1) EA003131B1 (de)
ES (1) ES2245034T3 (de)
IL (3) IL133277A0 (de)
NZ (1) NZ501424A (de)
PL (1) PL204503B1 (de)
PT (1) PT998556E (de)
SI (1) SI0998556T1 (de)
TR (1) TR200000181T2 (de)
WO (1) WO1999005175A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003510049A (ja) * 1999-09-23 2003-03-18 ライジェル・ファーマシューティカルズ・インコーポレイテッド Ｔｒａｆ４関連細胞周期タンパク質、組成物および使用法
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
NZ595386A (en) * 2005-08-11 2013-08-30 Arpi Matossian Rogers Peptides for treatment and diagnosis of autoimmune disease
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
EP2603524A1 (de) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta-bindende proteine
ES2653249T3 (es) * 2011-09-29 2018-02-06 Cellsnap, Llc Composiciones y métodos para ensayos de toxigenicidad

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2072356A1 (en) 1989-12-29 1991-06-30 James L. Urban Diagnosis and treatment of diseases
US5216132A (en) * 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
CA2101065A1 (en) * 1991-01-22 1992-07-23 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
US5480895A (en) * 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
US5891623A (en) * 1992-11-09 1999-04-06 Consorzio Per Le Biotecnologie Diagnosis and treatment of AIDS onset
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5589328A (en) * 1994-08-04 1996-12-31 Mahant; Vijay K. Chemiluminescence assays based on indoxyl substrates, thioindoxyl substrates and other substrates

Also Published As

Publication number Publication date
US6689359B1 (en) 2004-02-10
DE69830588D1 (de) 2005-07-21
KR20010022063A (ko) 2001-03-15
ATE297983T1 (de) 2005-07-15
PL338449A1 (en) 2000-11-06
KR20050046825A (ko) 2005-05-18
KR100567277B1 (ko) 2006-04-05
EA200000146A1 (ru) 2000-10-30
CN1264426A (zh) 2000-08-23
EA003131B1 (ru) 2003-02-27
JP2002511765A (ja) 2002-04-16
WO1999005175A2 (en) 1999-02-04
EP0998556B1 (de) 2005-06-15
SI0998556T1 (en) 2005-10-31
IL133277A (en) 2006-09-05
IL176076A (en) 2010-06-16
EP1595951A1 (de) 2005-11-16
PL204503B1 (pl) 2010-01-29
AU758455B2 (en) 2003-03-20
ES2245034T3 (es) 2005-12-16
AU8451798A (en) 1999-02-16
CN1330754C (zh) 2007-08-08
CA2296842A1 (en) 1999-02-04
PT998556E (pt) 2005-09-30
BR9810118A (pt) 2000-08-08
DE69830588T2 (de) 2006-05-04
KR100670070B1 (ko) 2007-01-19
NZ501424A (en) 2005-08-26
CU23412A3 (es) 2009-09-08
DK0998556T3 (da) 2005-10-17
TR200000181T2 (tr) 2000-05-22
CA2296842C (en) 2012-03-20
EP0998556A2 (de) 2000-05-10
US20050100541A1 (en) 2005-05-12
IL176076A0 (en) 2006-10-05
WO1999005175A3 (en) 1999-06-10

Similar Documents

Publication Publication Date Title
IL176076A0 (en) Ligands,including antibodies showing, reactivity against endocrine cells
HK1021025A1 (en) Process for in vitro detecting the presence or absence of antibodies to anti-tissue transglutinase from body fluids.
IL145535A0 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
MX9801687A (es) Compuestos y metodos para el diagnostico de tuberculosis.
WO2001000828A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2000034483A3 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2002059604A8 (en) Diagnosis and treatment of multiple sclerosis
ATE421531T1 (de) Apoptose-bezogene verbindungen und deren verwendung
WO2000000615A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
DK0687180T3 (da) Fremgangsmåde til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-anti
WO2001096372A3 (en) Zinc transporters proteins and their use in medicinal preparations
NO962596L (no) Nytt tumorsupressorgen
FI950962A (fi) Menetelmä anti-DNA-vasta-aineiden toteamiseksi, diagnostinen menetelmä, reagenssipakkaus ja lääkeaine autoimmuunisairauksia varten
WO2002088378A3 (en) 66784, a novel human potassium channel and uses therefor
AU4098201A (en) Method for diagnosing efficacy of xenotypic antibody therapy
WO2002034282A3 (en) Mammary secreted protein 36 (msp36) for cancer treatment and diagnosis
GB9715177D0 (en) Medicament
WO1999031274A3 (en) Reagents and methods useful for detecting diseases of the pancreas
WO2001027276A3 (en) Dna sequences from breast tumor and uses thereof
YU5002A (sh) Jedinjenja i postupci za lečenje i dijagnozu raka pluća
WO2002012327A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2004020666A3 (en) Diagnostic and therapeutic use of thyroid hormone binding protein for neurodegenerative diseases

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed